Clinical News

Dual therapy strategies for COPD: The scientific rationale for LAMA & LABAThere is a growing group of LAMA/LABA combination therapies in development. Investigations into the risks and benefits of LAMA/LABA therapy have demonstrated benefits.
PBM giants pare down drug expenses
PBM giants pare down drug expensesWhen Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.
ASPs vs. microbial resistance: Pharmacists lead the chargeThe Pew Charitable Trusts took a look at antibiotic stewardship programs in 10 U.S. health systems. Here's the result.
FDA approves trifluridine/tipiracil for colorectal cancerLonsurf is a new, orally administered cytotoxic drug for the treatment of patients with metastatic colorectal cancer.
Warfarin for CKD, aspirin for TIA, and what to do about ICHAnticoagulation briefs.
Efficacy and safety of LABA/LAMA combinations in COPD: A network meta-analysisUpdate: LABA/LAMA combo therapies
The GOLD guidelines and COPD treatmentThe results of a study indicated that only 36% of COPD patients were prescribed treatment according to the GOLD guidelines. The patients that were on GOLD-recommended pharmacological therapy had a moderate improvement in symptoms and health resource utilization.
FDA approves rolapitant to prevent chemotherapy-induced nausea and vomitingRolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.
USPSTF updates recommendations for aspirin useThe guidelines, which update the group's 2007 and 2009 recommendations, are published in the "Annals of Internal Medicine."
FDA warns about oral antifungal use during pregnancyA Danish study has found a possibility of increased risk of miscarriage in pregnant women who use oral fluconazole to treat yeast infections.